Scinai Immunotherapeutics Expands U.S. CDMO Agreement To $5.1M In Committed Base Services
October agreement advances the U.S. customer program to approximately $5.1 million in committed base servicesJERUSALEM, Nov. 5, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the
Share
Why It Matters
Scinai just made a bigger deal with a U.S. customer for making medicine. When companies grow their business deals, it shows people want their work.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.